Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of “Moderate Buy” from Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.50.

A number of equities analysts recently weighed in on KPTI shares. Piper Sandler decreased their price objective on Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, June 9th. Weiss Ratings downgraded shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Robert W. Baird lowered shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective for the company. in a report on Friday, July 31st. Finally, Wall Street Zen cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new position in shares of Karyopharm Therapeutics in the second quarter worth about $118,000. Bank of New York Mellon Corp purchased a new stake in Karyopharm Therapeutics during the 2nd quarter valued at about $559,000. Avidity Partners Management LP grew its position in Karyopharm Therapeutics by 244.6% during the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock worth $2,583,000 after acquiring an additional 329,175 shares during the last quarter. Royal Bank of Canada grew its position in Karyopharm Therapeutics by 4.1% during the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock worth $336,000 after acquiring an additional 2,399 shares during the last quarter. Finally, Commodore Capital LP purchased a new position in Karyopharm Therapeutics in the 1st quarter worth approximately $10,862,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI opened at $1.79 on Monday. The stock’s 50-day simple moving average is $5.27 and its two-hundred day simple moving average is $7.32. Karyopharm Therapeutics has a twelve month low of $1.72 and a twelve month high of $10.99. The company has a market capitalization of $40.60 million, a price-to-earnings ratio of -0.14 and a beta of 0.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by ($0.95). The business had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $32.19 million. On average, equities analysts expect that Karyopharm Therapeutics will post -4.7 earnings per share for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.